In a detailed comparison of two small-cap medical companies, Ekso Bionics and LENSAR, various factors highlight their respective strengths and weaknesses. This analysis focuses on institutional ownership, earnings, valuation, profitability, risk, and analyst recommendations, offering an insight into which company may hold superior potential for investors.
Institutional Ownership and Insider Holdings
Institutional ownership can significantly indicate a company’s market performance. Currently, 6.4% of Ekso Bionics’ shares are owned by institutional investors, a figure that pales in comparison to LENSAR, where institutional investors hold 40.2% of the shares. Insider ownership also differs notably; only 6.0% of Ekso Bionics shares are held by insiders, while a substantial 66.0% of LENSAR’s shares are in the hands of company insiders. This disparity suggests a higher level of confidence in LENSAR from both institutional and insider perspectives.
Financial Performance and Analyst Insights
When examining financial performance, key metrics such as gross revenue and earnings per share are crucial. Analysts have set a consensus target price of $10.50 for Ekso Bionics, indicating a potential upside of 91.96%. In contrast, LENSAR boasts a target price of $15.00, with a potential upside of 24.90%. This data positions Ekso Bionics as the more favorable option according to market analysts, given its higher upside potential.
Both companies exhibit distinct risk profiles as well. Ekso Bionics has a beta of 0.82, suggesting its share price is 18% less volatile than the S&P 500. LENSAR, with a beta of 0.66, is even less volatile, indicating a 34% reduction in share price fluctuation compared to the broader market. Such metrics are vital for investors considering their risk tolerance and investment strategies.
In terms of profitability, a comparative analysis of net margins, return on equity, and return on assets reveals that Ekso Bionics outperforms LENSAR in several categories, making it a compelling choice for those focused on financial health.
In summary, Ekso Bionics has shown stronger performance across nine of the fourteen evaluated factors when compared to LENSAR, particularly in areas crucial to financial viability and growth potential. It is essential for investors to consider these insights when making decisions regarding investments in these innovative medical technology companies.
Company Profiles
Ekso Bionics, founded in 2005 and based in San Rafael, California, specializes in the design and manufacture of exoskeleton products. The company operates through two primary segments: EksoHealth, which focuses on medical applications, and EksoWorks, which develops exoskeleton devices for industrial use. Their product lineup includes the EksoNR, a wearable device for rehabilitation, and the Ekso Indego, a powered lower-limb orthosis.
LENSAR, incorporated in 2004 and headquartered in Orlando, Florida, is a medical device company that develops femtosecond laser systems for cataract treatment. Their flagship product, the LENSAR Laser System, integrates advanced imaging and procedure planning technologies to facilitate optimal surgical outcomes. The ALLY Adaptive Cataract Treatment System represents another innovation, consolidating multiple laser functionalities into a single platform.
Investors considering opportunities in the medical technology sector can benefit from a thorough understanding of these two companies, their market positions, and the potential for future growth.
